# Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

> **NCT00643643** · PHASE2 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 41 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Maraviroc (UK-427,857)
- **DRUG:** Maraviroc (UK-427,857)
- **DRUG:** Maraviroc (UK-427,857)
- **DRUG:** Maraviroc (UK-427,857)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00643643
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2003-06
- **Final completion:** 2003-06
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2010-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00643643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00643643, "Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00643643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*